Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer

Journal of Clinical and Experimental Hepatology

Volumn 1, Issue 1, 2011, Pages 6-12

  Chapman, Michael H ^a,b   Sandanayake, Neomal S ^a,b   Andreola, Fausto ^a   Dhar, Dipok K ^a   Webster, George J ^a,b   Dooley, James S ^a   Pereira, Stephen P ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Biliary tract cancer; CA 19 9; CYFRA 21 1; Primary sclerosing cholangitis

Indexed keywords

CA 19-9 ANTIGEN; CYTOKERATIN 19 FRAGMENT;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BILIARY TRACT DISEASE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER STAGING; CANCER SURVIVAL; CHOLANGIOGRAPHY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

EID: 83455233869     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(11)60110-2     Document Type: Article

References (28)

1. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36:321-327.
2. Chalasani N, Baluyut A, Ismail A, et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000, 31:7-11.
3. Fisher A, Theise ND, Min A, et al. CA 19-9 does not predict cholangiocarcinoma in patients with primary sclerosing cholangitis undergoing liver transplantation. Liver Transpl Surg 1995, 1:94-98.
4. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000, 95:204-207.
5. Siqueira E, Schoen RE, Silverman W, et al. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis. Gastrointest Endose 2002, 56:40-47.
6. Lindberg B, Amelo U, Bergquist A, et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreaticography, with special reference to patients with primary sclerosing cholangitis. Endoscopy 2002, 34:909-916.
7. Mann DV, Edwards R, Ho S, Lau WY, Glazer G Elevated tumor marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000, 26:474-479.
8. Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Dig Dis Sci 2005, 50:1734-1740.
9. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumor cells in cancer patients by microchip technology. Nature 2007, 450:1235-1239.
10. Ntouroupi TG, Ashraf SQ, McGregor SB, et al. Detection of circulating tumor cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008, 99:789-795.
11. Maeda T, Kajiyama K, Adachi E, Takenaka K, Sugimachi K, Tsuneyoshi M The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol 1996, 9:901-909.
12. Takada M, Masuda N, Matsuura E, et al. Measurement of cytokeratin 19 fragments as a marker of lung cancer by CYFRA 21-1 enzyme immunoassay. Br J Cancer 1995, 71:160-165.
13. Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of CYFRA 21-1 compared with other tumor markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997, 33:385-391.
14. Andreadis C, Touloupidis S, Galaktidou G, Kortsaris AH, Boutis A, Mouratidou D Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. J Urol 2005, 174:1771-1775. discussion 1775-6.
15. Nakata B, Takashima T, Ogawa Y, Ishikawa T, Hirakawa K Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumor marker for detecting disease relapse and assessing treatment efficacy in breast cancer. Br J Cancer 2004, 91:873-878.
16. Nakata B, Chung YS, Kato Y, et al. Clinical significance of serum CYFRA 21-1 in gastric cancer. Br J Cancer 1996, 73:1529-1532.
17. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004, 90:2097-2105.
18. Kashihara T, Ohki A, Kobayashi T, et al. Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level. J Gastroenterol 1998, 33:447-453.
19. Uenishi T, Yamazaki O, Tanaka H, et al. Serum cytokeratin 19 fragment (CYFRA 21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008, 15:583-589.
20. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 1980, 21:870-877.
21. Moreno Luna LE, Gores GJ Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver Transpl 2006, 12(Suppl 2):S15-S19.
22. Tischendorf JJ, Kruger M, Trautwein C, et al. Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006, 38:665-669.
23. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM Biliary tract cancers. N Engl J Med 1999, 341:1368-1378.
24. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001, 234:507-517. discussion 517-9.
25. Farley DR, Weaver AL, Nagorney DM " Natural history" of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995, 70:425-429.
26. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 2008, 248:273-279.
27. Charatcharoenwitthaya P, Enders FB, Hailing KC, Lindor KD Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology 2008, 48:1106-1117.
28. Liu L, Liao GQ, He P, et al. Detection of circulating cancer cells in lung cancer patients with a panel of marker genes. Biochem Biophys Res Commun 2008, 372:756-760.